AlzeCure Pharma AB (publ)
Stockholm Stock Exchange ALZCUR.ST
AlzeCure Pharma AB (publ) EBIT for the year ending December 31, 2023: USD -3.78 M
-
AlzeCure Pharma AB (publ) EBIT for the year ending December 31, 2022 was USD -5.37 M, a 37.28% change year over year.
-
AlzeCure Pharma AB (publ) EBIT for the year ending December 31, 2021 was USD -8.56 M, a 0.99% change year over year.
-
AlzeCure Pharma AB (publ) EBIT for the year ending December 31, 2020 was USD -8.65 M, a -59.84% change year over year.
-
AlzeCure Pharma AB (publ) EBIT for the year ending December 31, 2019 was USD -5.41 M, a -33.10% change year over year.
| Date | EBIT | EBITDA | Net Income | EPS (Diluted) |
|---|
| CEO | Mr. Martin Jönsson |
| IPO Date | Nov. 28, 2018 |
| Location | Sweden |
| Headquarters | HAelsovAegen 7 |
| Employees | 11 |
| Sector | Health Care |
| Industries | |
AlzeCure Pharma AB (publ), a pharmaceutical company, develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is developing drug candidates based on the NeuroRestore, Alzstatin, and Painless research platforms. Its pipeline drug candidates include ACD856, which is in phase I clinical trial for Alzheimer's disease, sleep disorders, traumatic brain injuries, and Parkinson's disease; ACD857, ACD679, and ACD680 for Alzheimer's disease; ACD440, a TRPV1 antagonist that has completed phase I clinical trial for neuropathic pain; and TrkA-NAM for osteoarthritic pain. The company was founded in 2012 and is based in Huddinge, Sweden.
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email